Pharmacodynamic monitoring of factor VIII replacement therapy in hemophilia A: Combining thrombin and plasmin generation
Open Access
- 26 September 2020
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 18 (12) , 3222-3231
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- The World Federation of Hemophilia guideline on management of haemophiliaHaemophilia, 2012
- Guidelines for the management of hemophiliaHaemophilia, 2012
- Low‐titre inhibitors, undetectable by the Nijmegen assay, reduce factor VIII half‐life after immune tolerance inductionJournal of Thrombosis and Haemostasis, 2012
- Simultaneous thrombin and plasmin generation capacities in normal and abnormal states of coagulation and fibrinolysis in children and adultsThrombosis Research, 2011
- Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgeryBlood, 2010
- Measurement of global haemostasis in severe haemophilia A following factor VIII infusionBritish Journal of Haematology, 2007
- Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decisionHaemophilia, 2005
- Thrombin generation and phenotypic correlation in haemophilia AHaemophilia, 2005
- Evaluation of thrombin generating capacity in plasma from patients with haemophilia A and BThrombosis and Haemostasis, 2005
- The Hemophilias — From Royal Genes to Gene TherapyNew England Journal of Medicine, 2001